<DOC>
	<DOCNO>NCT00304135</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil , cisplatin , oxaliplatin , gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Radiation therapy use high-energy x-ray kill tumor cell . It yet know whether give fluorouracil cisplatin together radiation therapy effective give gemcitabine together oxaliplatin treat nonmetastatic biliary tract cancer . PURPOSE : This randomized phase II/III trial study fluorouracil , cisplatin , radiation therapy see well work compare gemcitabine oxaliplatin treat patient nonmetastatic biliary tract cancer remove surgery .</brief_summary>
	<brief_title>Fluorouracil , Cisplatin , Radiation Therapy Gemcitabine Oxaliplatin Treating Patients With Nonmetastatic Biliary Tract Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare 3-month progression rate patient unresectable , nonmetastatic cancer biliary tract treat fluorouracil , cisplatin , radiotherapy v gemcitabine hydrochloride oxaliplatin . ( phase II ) - Compare overall survival patient treat regimen . ( phase III ) Secondary - Compare toxicity regimens patient . ( phase II ) - Compare quality life initial drainage ( phase II ) overall ( phase III ) patient treat regimen . - Compare biliary complication rate patient treat regimen . - Compare duration hospitalization patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord disease location ( gallbladder v intrahepatic biliary duct v extrahepatic biliary duct ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo radiotherapy daily , 5 day week day 1-33 . Patients also receive fluorouracil IV continuously 5 day week week 1-5 cisplatin IV 15 minute day 1-4 29-32 ( day 1 2 29 30 ) absence disease progression unacceptable toxicity . - Arm II : Patients receive gemcitabine hydrochloride IV 100 minute oxaliplatin IV 2 hour day 1 . Treatment repeat every 14 day 12 course absence disease progression unacceptable toxicity . Quality life assess baseline every 3 month thereafter . After completion study therapy , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 170 patient accrue study .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer biliary tract 1 follow method : Histologic confirmation Stenosis biliary tract MRI , CT scan , ECHO Unresectable disease Amenable radiotherapy No visceral metastasis image Hepatic adenopathy include radiation field allow No known ampulla Vater pancreatic cancer involve biliary tract PATIENT CHARACTERISTICS : WHO performance status 02 Creatinine &lt; 1.5 mg/dL Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 75,000/mm^3 Prothrombin time &gt; 70 % Bilirubin ≤ 2.9 mg/dL ( hepatic draining , need ) No unstable angina No symptomatic cardiac insufficiency No comorbidity would preclude study therapy No prior malignancy except basal cell skin cancer carcinoma situ cervix No prior hydatid cyst alveolar echinococciasis Not pregnant nursing PRIOR CONCURRENT THERAPY : No recent biliary surgery No hepatic intraarterial chemotherapy No prior anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
</DOC>